предыдущий|следующий

Прогресс исследований по регулированию микробиоты кишечника традиционной китайской медициной для вмешательства при злокачественных опухолях пищеварительной системы

  • role： First author第一作者
  • Affiliation：

    School of Sports Medicine and Health， Chengdu Sport University， Chengdu 641418， China

  • Email：315208912@qq.com
  • Introduction：朱禹，博士，讲师，从事中医药防治肿瘤及代谢性疾病研究，E-mail：315208912@qq.com
ZHU Yu1,  
  • Affiliation：

    Chengdu University of Traditional Chinese Medicine（TCM）， Chengdu 610032， China

    Hospital of Chengdu University of TCM， Chengdu 610072， China

HUANG Ju23,  
  • Affiliation：

    Shuguang Hospital， Shanghai University of TCM， Shanghai 200021， China

CHEN Nianzhi4,  
  • role： Corresponding author通信作者
  • Affiliation：

    Chengdu University of Traditional Chinese Medicine（TCM）， Chengdu 610032， China

    Hospital of Chengdu University of TCM， Chengdu 610072， China

  • Email：1121174213@qq.com
  • Introduction：罗成，博士，医师，从事中医药防治呼吸病与老年病的临床研究，E-mail：1121174213@qq.com； *
LUO Cheng23*,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Sports Medicine and Health， Chengdu Sport University， Chengdu 641418， China

  • Email：cdutcmwu@163.com
  • Introduction：吴贤波，博士，教授，博士生导师，从事中医药防治肿瘤及代谢性疾病研究，E-mail：cdutcmwu@163.com
WU Xianbo1*

реферат

Злокачественные опухоли пищеварительной системы (DT) являются одной из основных причин смертности в мире и представляют значительное экономическое бремя. Микробиота кишечника играет ключевую роль в поддержании здоровья хозяина, включая обеспечение питательными веществами, защиту от патогенов и стимулирование развития иммунной системы. В последние годы все больше исследований показывают тесную связь дисбактериоза кишечника с такими DT, как рак желудка, печени и толстой кишки. Следовательно, таргетированная модуляция кишечной микробиоты имеет потенциал для подавления роста и метастазирования DT, хотя конкретные механизмы регуляции остаются неясными. С углублением исследований китайской традиционной медицины в области противоопухолевой терапии, особенно многочисленных фундаментальных и клинических исследований по регулированию микробиоты кишечника, данный подход привлекает значительное внимание в лечении DT. В статье приведен систематический обзор взаимоотношений между кишечной микробиотой и DT, а также исследований по регуляции микробиоты кишечника китайской традиционной медициной для борьбы с DT с целью обеспечения основ и направлений для будущих фундаментальных и клинических исследований DT. Анализ литературы показывает, что микробиота кишечника влияет на возникновение и развитие DT через различные пути, включая вызов хронического воспаления, производство канцерогенных метаболитов, индукцию нестабильности генома, регуляцию иммунной системы и изменение микроокружения опухоли. Китайская традиционная медицина может оказывать противоопухолевое действие путем коррекции состава микробиоты кишечника, регуляции метаболитов микробиоты, восстановления функции кишечного барьера и влияния на иммунную функцию. Поэтому понимание взаимосвязи между микробиотой кишечника и DT, а также механизмов регуляции китайской традиционной медицины может способствовать разработке новых стратегий профилактики и лечения DT.

ключеви́че слова́

микробиота кишечника; злокачественные опухоли пищеварительной системы; традиционная китайская медицина; иммунитет; регуляция метаболитов

References

  1. 1.
    BRAY F，LAVERSANNE M，SUNG H，et al.Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2024，74（3）：229-263.
  2. 2.
    MULLARD A.Addressing cancer's grand challenges［J］.Nat Rev Drug Discov，2020，19（12）：825-826.
  3. 3.
    LIU X Y，CHEN Y J，ZHANG S，et al.Gut microbiota-mediated immunomodulation in tumor［J］.J Exp Clin Cancer Res，2021，40（1）：221.
  4. 4.
    LIAO Y，WEN Y P，LIU L S.Intervention of lung cancer by Chinese medicine and active components via affecting gut microbiota：A review［J］.Chin J Exp Tradit Med Form，2023，29（24）：194-201.
  5. 5.
    LUO C，YE Y H，ZHENG L，et al.Research progress of traditional Chinese medicine based on "lung-intestinal" axis regulating intestinal flora in the treatment of severe pneumonia［J］.China Med Herald，2023，20（6）：33-36.
  6. 6.
    LUO C ，YE Y H，SHENG G G，et al.Research progress of Xuanbai Chengqi decoction and its additive prescription in the treatment of respiratory diseases［J］.Chin Tradit Pat Med，2023，45（10）：3369-3375.
  7. 7.
    PARK E M，CHELVANAMBI M，BHUTIANI N，et al.Targeting the gut and tumor microbiota in cancer［J］.Nat Med，2022，28（4）：690-703.
  8. 8.
    SIMPSON R C，SHANAHAN E R，SCOLYER R A，et al.Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors［J］.Nat Rev Clin Oncol，2023，20（10）：697-715.
  9. 9.
    ZHOU C B，ZHOU Y L，FANG J Y.Gut microbiota in cancer immune response and immunotherapy［J］.Trends Cancer，2021，7（7）：647-660.
  10. 10.
    SHAH S C，ITZKOWITZ S H.Colorectal cancer in inflammatory bowel disease：Mechanisms and management［J］.Gastroenterology，2022，162（3）：715-730.
  11. 11.
    LUO C，YE Y H，KE J.Effect of inflammation on lung cancer based on theory of "Zhuang Huo Shi Qi"［J］.Acta Chin Med，2024，39（4）：689-694.
  12. 12.
    LUO C，YE Y H，KE J.Exploring the lung "inflammation and cancer transformation" and prevention ideas based on the theory of "Zhuang Huo Shi Qi"［J］.J Sichuan Tradit Chin Med，2024，42（3）：61-64.
  13. 13.
    ZOU Y Q，WANG S L，ZHANG H H，et al.The triangular relationship between traditional Chinese medicines，intestinal flora，and colorectal cancer［J］.Med Res Rev，2024，44（2）：539-567.
  14. 14.
    FENG X L，LI Z H，GUO W H，et al.The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation：A review［J］.Front Immunol，2023，14：1087755.
  15. 15.
    HUANG M G，XIE S，WANG J X，et al.Chinese medicine in treatment of ulcerative colitis by regulating intestinal flora：A review［J］.Chin J Exp Tradit Med Form，2024，30（2）：267-275.
  16. 16.
    GAO R Y，WU C Y，ZHU Y F，et al.Integrated analysis of colorectal cancer reveals cross-cohort gut microbial signatures and associated serum metabolites［J］.Gastroenterology，2022，163（4）：1024-1037.
  17. 17.
    BAI X W，WEI H，LIU W X，et al.Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites［J］.Gut，2022，71（12）：2439-2450.
  18. 18.
    YACHIDA S，MIZUTANI S，SHIROMA H，et al.Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer［J］.Nat Med，2019，25（6）：968-976.
  19. 19.
    BERTOCCHI A，CARLONI S，RAVENDA P S，et al.Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver［J］.Cancer Cell，2021，39（5）：708-724.
  20. 20.
    DZIUBAŃSKA-KUSIBAB P J，BERGER H，BATTISTINI F，et al.Colibactin DNA-damage signature indicates mutational impact in colorectal cancer［J］.Nat Med，2020，26（7）：1063-1069.
  21. 21.
    WONG C C，YU J.Gut microbiota in colorectal cancer development and therapy［J］.Nat Rev Clin Oncol，2023，20（7）：429-452.
  22. 22.
    GALEANO NIÑO J L，WU H R，LACOURSE K D，et al.Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer［J］.Nature，2022，611（7937）：810-817.
  23. 23.
    SINGH N，GURAV A，SIVAPRAKASAM S，et al.Activation of Gpr109a，receptor for niacin and the commensal metabolite butyrate，suppresses colonic inflammation and carcinogenesis［J］.Immunity，2014，40（1）：128-139.
  24. 24.
    CREMONESI E，GOVERNA V，GARZON J F G，et al.Gut microbiota modulate T cell trafficking into human colorectal cancer［J］.Gut，2018，67（11）：1984-1994.
  25. 25.
    SECHER T，NORMAND S，CHAMAILLARD M.NOD2 prevents emergence of disease-predisposing microbiota［J］.Gut Microbes，2013，4（4）：353-356.
  26. 26.
    ZHU H B，XU W Y，HU Z Q，et al.RNA virus receptor Rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer［J］.J Exp Clin Cancer Res，2017，36（1）：2.
  27. 27.
    KESSELRING R，GLAESNER J，HIERGEIST A，et al.IRAK-M expression in tumor cells supports colorectal cancer progression through reduction of antimicrobial defense and stabilization of STAT3［J］.Cancer Cell，2016，29（5）：684-696.
  28. 28.
    MAN S M，ZHU Q F，ZHU L Q，et al.Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer［J］.Cell，2015，162（1）：45-58.
  29. 29.
    ZHANG X Y，ZHAO S W，SONG X B，et al.Inhibition effect of Glycyrrhiza polysaccharide （GCP） on tumor growth through regulation of the gut microbiota composition［J］.J Pharmacol Sci，2018，137（4）：324-332.
  30. 30.
    SUN Q，YANG H，LIU M L，et al.Berberine suppresses colorectal cancer by regulation of Hedgehog signaling pathway activity and gut microbiota［J］.Phytomedicine，2022，103：154227.
  31. 31.
    CHEN H T，YE C X，WU C H，et al.Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine［J］.Int J Biol Sci，2023，19（7）：2097-2113.
  32. 32.
    ZHU L Q，ZHANG L，ZHANG J，et al.Evodiamine inhibits high-fat diet-induced colitis-associated cancer in mice through regulating the gut microbiota［J］.J Integr Med，2021，19（1）：56-65.
  33. 33.
    WEI J，ZHENG Z M，HOU X X，et al.Baicalin modulates gut microbiota and inhibits liver metastasis of colorectal cancer induced by high-fat diet［J］.Shanghai J Tradit Chin Med，2023，57（10）：59-67.
  34. 34.
    GUO C L，GUO D D，FANG L，et al.Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon［J］.Carbohydr Polym，2021，267：118231.
  35. 35.
    GOU H Y，SU H，LIU D H，et al.Traditional medicine pien tze Huang suppresses colorectal tumorigenesis through restoring gut microbiota and metabolites［J］.Gastroenterology，2023，165（6）：1404-1419.
  36. 36.
    ZHANG Z Z，SHAO S Y，ZHANG Y R，et al.Xiaoyaosan slows cancer progression and ameliorates gut dysbiosis in mice with chronic restraint stress and colorectal cancer xenografts［J］.Biomed Pharmacother，2020，132：110916.
  37. 37.
    SUI H，ZHANG L，GU K J，et al.YYFZBJS ameliorates colorectal cancer progression in ApcMin/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation［J］.Cell Commun Signal，2020，18（1）：113.
  38. 38.
    LYU J，JIA Y T，LI J，et al.Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment［J］.Cell Death Dis，2019，10（6）：415.
  39. 39.
    YE C X，WU C H，LI Y，et al.Traditional medicine Xianglian pill suppresses high-fat diet-related colorectal cancer via inactivating TLR4/MyD88 by remodeling gut microbiota composition and bile acid metabolism［J］.J Ethnopharmacol，2024，333：118411.
  40. 40.
    RAY K.Gut microbiota：Obesity-induced microbial metabolite promotes HCC［J］.Nat Rev Gastroenterol Hepatol，2013，10（8）：442.
  41. 41.
    SCHNABL B，BRENNER D A.Interactions between the intestinal microbiome and liver diseases［J］.Gastroenterology，2014，146（6）：1513-1524.
  42. 42.
    ZHOU Y，HU L，TANG W Q，et al. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism［J］.J Hematol Oncol，2021，14（1）：9.
  43. 43.
    QIN N，YANG F L，LI A，et al.Alterations of the human gut microbiome in liver cirrhosis［J］.Nature，2014，513（7516）：59-64.
  44. 44.
    YU L X，YAN H X，LIU Q，et al.Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents［J］.Hepatology，2010，52（4）：1322-1333.
  45. 45.
    DAPITO D H，MENCIN A，GWAK G Y，et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4［J］.Cancer Cell，2012，21（4）：504-516.
  46. 46.
    SCHWABE R F，GRETEN T F.Gut microbiome in HCC—Mechanisms，diagnosis and therapy［J］.J Hepatol，2020，72（2）：230-238.
  47. 47.
    PONZIANI F R，BHOORI S，CASTELLI C，et al.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease［J］.Hepatology，2019，69（1）：107-120.
  48. 48.
    ZHANG X，COKER O O，CHU E S，et al.Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites［J］.Gut，2021，70（4）：761-774.
  49. 49.
    FENG D，WANG J，JIANG Y J，et al.Effects of total glycosides of Cistanche deserticola on HepG2 hepatoma-bearing mice［J］.Food Sci，2024，45（6）：120-129.
  50. 50.
    TIAN L，WAN D J，WEN Y M.Effect of salvianolic acid B on TLR4/MyD88/NF-κB pathway and intestinal bacteria in H22 tumor-bearing mice［J］.World Sci Technol Mod Tradit Chin Med Mater Med，2023，25（5）：1871-1878.
  51. 51.
    YU L，SUN C，ZHANG M X.Regulation of intestinal floras and their metabolism functions by Ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer［J］.J Pract Hepatol，2021，24（4）：476-479
  52. 52.
    TIAN L，WAN D J，QIU D Y，et al.Effect of ursolic acid on anti-tumor and intestinal bacterial community structure and diversity in H22 tumor-bearing mice［J］.Sci Technol Food Ind，2021，42（4）：86-91.
  53. 53.
    HAN D D，HU M F，YU C.Effect of Diwu Yanggan decoction on intestinal flora in liver cancer model through regulating TLR4/NF-κB signal pathway［J］.J Liaoning Univ Tradit Chin Med，2023，25（11）：68-72.
  54. 54.
    ZHANG Y M，ZHU L，SHI J，et al.Effects of Yinchenhao decoction on hepatic bile acid and intestinal microecology in mice with orthotopic transplantation of hepatocellular carcinoma［J］.Guangming J Chin Med，2022，37（16）：2939-2942.
  55. 55.
    LI S S，PU W Y，LING Y，et al.Sanwubai powder reversing Th1/Th2 drift by affecting FXR expression and exerting anti-liver cancer immune response［J］.Acta Chin Med，2021，36（5）：1021-1028
  56. 56.
    GUO Q Q，QIN H，LIU X L，et al.The emerging roles of human gut microbiota in gastrointestinal cancer［J］.Front Immunol，2022，13：915047.
  57. 57.
    ZHANG W，ZHOU Y N，FAN Y T，et al.Metal-organic-framework-based hydrogen-release platform for multieffective Helicobacter pylori targeting therapy and intestinal flora protective capabilities［J］.Adv Mater，2022，34（2）：e2105738.
  58. 58.
    FERREIRA R M，PEREIRA-MARQUES J，PINTO-RIBEIRO I，et al.Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota［J］.Gut，2018，67（2）：226-236.
  59. 59.
    GUO Y，ZHANG Y，GERHARD M，et al.Effect of Helicobacter pylori on gastrointestinal microbiota：A population-based study in Linqu，a high-risk area of gastric cancer［J］.Gut，2020，69（9）：1598-1607.
  60. 60.
    LI T H，QIN Y W，SHAM P C，et al.Alterations in gastric microbiota after H. pylori eradication and in different histological stages of gastric carcinogenesis［J］.Sci Rep，2017，7（1/4）：44935.
  61. 61.
    SUNG J J Y，COKER O O，CHU E，et al.Gastric microbes associated with gastric inflammation，atrophy and intestinal Metaplasia 1 year after Helicobacter pylori eradication［J］.Gut，2020，69（9）：1572-1580.
  62. 62.
    FU K L，CHEUNG A H K，WONG C C，et al.Streptococcus anginosus promotes gastric inflammation，atrophy，and tumorigenesis in mice［J］.Cell，2024，187（4）：882-896.
  63. 63.
    LI Q，WU W，GONG D X，et al.Correction to：Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling［J］.Gastric Cancer，2022，25（6）：1139-1141.
  64. 64.
    DENG R，YU S Y，RUAN X Q，et al.Capsaicin orchestrates metastasis in gastric cancer via modulating expression of TRPV1 channels and driving gut microbiota disorder［J］.Cell Commun Signal，2023，21（1）：364.
  65. 65.
    BAI X，CHENG F E，YANG C Y，et al.Mechanism of Eremias multiocellata on inhibiting gastric cancer with liver metastasis based on SNAIL signaling pathway and gut microbiota［J］.Chin Tradit Herb Drugs，2023，54（3）：825-833.
  66. 66.
    ZHANG Y，LU F G，SONG P H，et al.Effect of ursolic acid on tumor inhibition and intestinal flora of mice transplanted with SCG-7901 tumor cells［J］.Anat Res，2021，43（3）：199-205.
  67. 67.
    CHEN Y L，CHEN X，ZHANG R J，et al.Study on the effect of modified Buzhong Yiqi prescription on intestinal flora of gastric tumor carrying mice based on 16S rRNA high-throughput sequencing technology［J］.Jiangsu J Tradit Chin Med，2022，54（8）：70-75.
  68. 68.
    BIAN Y Q，CHEN X，CAO H Y，et al.A correlational study of Weifuchun and its clinical effect on intestinal flora in precancerous lesions of gastric cancer［J］.Chin Med，2021，16（1）：120.
  69. 69.
    ZHAO T T，YU Z J.Modified Gexia-Zhuyu Tang inhibits gastric cancer progression by restoring gut microbiota and regulating pyroptosis［J］.Cancer Cell Int，2024，24（1）：21.

Читать полностью

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website